Wilms Tumor Treatment Advances: A Comprehensive Review

Treatment Advances in Wilms Tumor: A Review

Abstract:

Wilms tumor, also known as nephroblastoma, is the most common pediatric renal malignancy. While the current standard of care includes surgery, chemotherapy, and radiation therapy, recent advancements in understanding Wilms tumor's molecular biology have led to promising new treatment strategies, such as targeted therapy and immunotherapy. This review summarizes current treatment options and highlights recent progress in the field.

Introduction:

Wilms tumor is a type of kidney cancer primarily affecting children. It accounts for approximately 6% of all childhood cancers (1). The tumor originates from nephrogenic blastemal cells, embryonic cells that develop into the kidney. The standard treatment for Wilms tumor combines surgery, chemotherapy, and radiation therapy. However, new treatment approaches, like targeted therapy and immunotherapy, are emerging based on a deeper understanding of the tumor's molecular biology.

Surgery:

Surgery is the primary treatment for Wilms tumor. The aim of surgery is to remove the tumor and any surrounding tissue that may contain cancer cells. The surgical approach depends on the size and location of the tumor. For smaller tumors, a partial nephrectomy may be performed, removing only the affected part of the kidney. Larger tumors require a radical nephrectomy, removing the entire kidney. In some cases, surgery may be followed by chemotherapy and/or radiation therapy.

Chemotherapy:

Chemotherapy is a systemic treatment using drugs to kill cancer cells throughout the body. Typically given after surgery, chemotherapy aims to destroy any remaining cancer cells and reduce recurrence risk. The most commonly used chemotherapy drugs for Wilms tumor include vincristine, actinomycin D, and doxorubicin. These drugs are usually administered in combination over several months.

Radiation Therapy:

Radiation therapy uses high-energy radiation to kill cancer cells. It is commonly used in conjunction with surgery and chemotherapy for Wilms tumor. Radiation therapy is typically given after surgery and chemotherapy to eliminate any remaining cancer cells. The radiation is targeted to the area where the tumor was located, protecting surrounding tissues as much as possible. However, radiation therapy can have long-term side effects, such as an increased risk of secondary cancers and kidney damage.

Targeted Therapy:

Targeted therapy employs drugs to target specific molecules involved in cancer cell growth and spread. Based on understanding the molecular biology of cancer and identifying targets unique to cancer cells, targeted therapy holds promise for Wilms tumor treatment. One particularly promising target is the anaplastic lymphoma kinase (ALK) gene, mutated in approximately 10% of Wilms tumor cases (2). Crizotinib, a drug targeting ALK, has shown promising results in preclinical studies and is currently being evaluated in clinical trials (3).

Immunotherapy:

Immunotherapy utilizes the body's immune system to fight cancer. It works by stimulating the immune system to recognize and attack cancer cells. One of the most promising immunotherapy approaches for Wilms tumor is chimeric antigen receptor (CAR) T-cell therapy. In CAR T-cell therapy, a patient's own T-cells are genetically modified to express a receptor that recognizes and binds to a specific antigen on the surface of cancer cells. Once modified, these T-cells are infused back into the patient, where they can recognize and kill cancer cells. CAR T-cell therapy has shown promising results in preclinical studies and is currently being evaluated in clinical trials (4).

Conclusion:

Wilms tumor is a complex disease requiring a multidisciplinary approach to treatment. While the current standard of care involves a combination of surgery, chemotherapy, and radiation therapy, recent advancements in understanding Wilms tumor's molecular biology have led to the development of new treatment strategies, such as targeted therapy and immunotherapy. These new approaches have the potential to improve outcomes for patients with Wilms tumor and reduce the long-term side effects of treatment.

References:

1. Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015 Dec 10;33(35):3716-24.

2. Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11p15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a Children's Oncology Group study. J Clin Oncol. 2011;29(6):698-703.

3. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472-480.

4. Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017;31(10):2469-2472.